BD Diagnostics, a segment of Becton, Dickinson and Company (BD; Burlington, N.C.) has received U.S. Food and Drug Administration (FDA) premarket approval for its BD FocalPoint GS Imaging System. This new system is designed to enhance cervical cancer screening for cytology laboratories, using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma, and their usual precursor conditions.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2009 - Table of Contents

DTTR January 2009 (full PDF issue)

Genentech Files Petition with FDA Urging Regulation of Lab-Developed Tests

Rosetta Genomics Launches First Test

Invitrogen, Applied Biosystems Close on $6.7 Billion Merger Deal

HHS Report Examines Potential of Molecular Medicine

LabCorp, National Jewish Health to Collaborate on Molecular Diagnostics

American College of Physicians Releases Guidance on HIV Screening

New Study Findings May Aid in Breast Cancer Diagnosis, Treatment Selection

Gene Networks May Predict Leukemia Growth Rate

BD Receives FDA Approval for Cervical Cancer Screening System

Protein Levels Indicate Risk of Death in Colorectal Cancer Patients

Clarient Introduces Second Genetic Test for Colorectal Cancer

Esoteric Testing Fuels 11% Q3 Revenue Growth at LabCorp

Roche Gets CE Mark for New HIV, HBV Viral Load Tests

Tom Daschle Nominated for HHS Secretary

Abaxis Gets CLIA Waiver for Point-of-Care Test Panels

Gene Express, BioTrove to Co-Market Lung Cancer Test

Diagnoplex, Generation Health Close on Funding Rounds

IVD Stocks Down 12%; Affymetrix Falls 30%

Learn From Leaders in Molecular Diagnostics